Please login to the form below

Not currently logged in
Email:
Password:

Zynteglo

This page shows the latest Zynteglo news and features for those working in and with pharma, biotech and healthcare.

EMA fast-tracks review of bluebird bio’s LentiGlobin for sickle cell disease

EMA fast-tracks review of bluebird bio’s LentiGlobin for sickle cell disease

LentiGlobin is approved under the brand name Zynteglo in Europe for the treatment of dependent beta thalassaemia (TDT) who do not have a matching donor for a stem cell transplant.

Latest news

More from news
Approximately 4 fully matching, plus 14 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

The other side of … Crohn’s disease
What patients say is their truth about living with chronic conditions. “I want to believe in my doctor but I feel more comfortable getting my guidance elsewhere.”...
OPEN Health brings the Best of Both Worlds to MAPS EMEA 2020
...
1000 Voices Survey
The patient voice is key to creating meaningful changes in healthcare; to drive patients to be more actively involved in their care, which leads to better outcomes. So, we went...

Infographics